CMS stance on carotid stenting ignores science, kills innovation, SCAI doc argues

04/29/2013 | CardiovascularBusiness.com

Carotid stent therapy has been shown to be as effective as surgery in low-risk asymptomatic patients, yet CMS has upheld a 25-year-old noncoverage stance, without explanation, writes Dr. Christopher White, SCAI's immediate past president. Many observers believe CMS' position is the result of "turf battles," which have permitted the agency to disregard scientific results and to stifle medical innovation, Dr. White writes. The result, he says, is that patients are unable to opt for the treatment that may be best for them.

View Full Article in:

CardiovascularBusiness.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC